A PHASE 2-3, MULTICENTER, RANDOMIZED, DOUBLEBLIND
STUDY OF SELINEXOR (KPT-330) VERSUS
PLACEBO IN PATIENTS WITH ADVANCED
UNRESECTABLE DEDIFFERENTIATED
LIPOSARCOMA (DDLS)
How understandable was the trial content above?
Hard to understand
Easy to understand